Obstructive Sleep Apnea: Nacystelyn Inhaler Study

We are testing a new inhaler treatment for people with obstructive sleep apnea to see if it helps improve symptoms and reduce oxidative stress. The study also looks at the safety of this new treatment.

≤3 months≤5 visitsEfficacy phase (II)Cost ReimbursementStandard MedicinesOralNeurologyPsychiatryPulmonology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Acetylcysteine
Acetylcysteine helps thin and loosen mucus to clear airways in respiratory conditions and treats acetaminophen (paracetamol) overdose.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Pneumocare
Sleep Laboratory
Jambes, Belgium
HUmani
Pneumology
Montigny-le-Tilleul, Belgium
Centre Hospitalier Universitaire Grenoble Alpes
Pneumology/Physiology, Sleep and Exercise
La Tronche, France
Sponsor: Laboratoires S.M.B.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.